Lb Pharmaceuticals Inc (LBRX) valuation
Lb Pharmaceuticals P/E ratio history
Lb Pharmaceuticals trades at 1.7 times its earnings over the last twelve months.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $22.26 | — | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Lb Pharmaceuticals valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Lb PharmaceuticalsLBRX | $1.14B | 1.7 | — | — |
| EnovisENOV | $1.15B | — | 5.6 | 0.5 |
| Castle BiosciencesCSTL | $1.13B | — | — | 3.2 |
| Bioventus Class ABVS | $1.11B | 17.3 | 15.7 | 1.9 |
| Omada HealthOMDA | $1.11B | 17.5 | 37.8 | 3.6 |
| ArtivionAORT | $1.10B | — | 39.4 | 2.3 |
| Lumexa ImagingLMRI | $1.10B | — | — | — |
| Procept BioroboticsPRCT | $1.09B | — | — | 3.2 |
| Taysha Gene TherapiesTSHA | $1.19B | — | — | 216.4 |
| Peer median | 17.4 | 26.7 | 3.2 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: LBRX returns
No forecast, no recommendation. This page describes Lb Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.